Loading…
Checkpoint Kinase 2 (CHEK2) Gene Mutation in a Patient With Breast and Prostate Cancer: A Unique Presentation of a Rare Disease
Breast cancer is one of the rarest malignancies in males, with a low incidence rate compared to all breast cancers. Gene mutation plays a significant role in the pathologic process of cancer. Mutations in breast cancer gene 1 ( ) and breast cancer gene 2 ( ) have been associated with male breast can...
Saved in:
Published in: | Curēus (Palo Alto, CA) CA), 2023-11, Vol.15 (11), p.e49710 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c211t-3180863a6d1979f86feff8b864bc65947d297f4644c814f0f0f7947632fbbfd73 |
container_end_page | |
container_issue | 11 |
container_start_page | e49710 |
container_title | Curēus (Palo Alto, CA) |
container_volume | 15 |
creator | Ekram, Samar N Al Shanbari, Nasser Bin Laswad, Bassam M Alharthi, Abdulrahman Tayeb, Waseem Bahha, Abdulbari |
description | Breast cancer is one of the rarest malignancies in males, with a low incidence rate compared to all breast cancers. Gene mutation plays a significant role in the pathologic process of cancer. Mutations in breast cancer gene 1 (
) and breast cancer gene 2 (
) have been associated with male breast cancer (MBC), as well as prostate cancer (PCa). Despite the etiopathogenetic similarity, combined MBC and PCa is a rare entity. This report presents the case of a 57-year-old male with a history of breast cancer who underwent modified radical mastectomy (MRM) with lymph node dissection followed by adjuvant chemoradiotherapy four years ago. The patient presented with recurrent episodes of voiding dysfunction for three months, followed by urine retention. His family history was positive for breast and lung cancer. High prostate-specific antigen (PSA) and Prostate Imaging-Reporting and Data System 5 (PI-RADS5) necessitate transrectal ultrasound-guided biopsy, which confirmed the diagnosis of PCa. Molecular genetics testing and next-generation sequencing (NGS) analysis identified heterozygous variant c.636T>G, p.(Tyr212*) in the checkpoint kinase 2 (
) gene. The patient is planned for neoadjuvant luteinizing hormone-releasing hormone (LHRH) for 3-6 months, to be followed by transurethral tunneling of the prostate (TUTP) with adjuvant LHRH. The allele frequency of this patient mutation was documented for the first time among the general population, and it has not been described in the literature. This unique and rare case was presented with clinical, morphological, and immunohistochemical features together with a review of the current literature. |
doi_str_mv | 10.7759/cureus.49710 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2908074111</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2908074111</sourcerecordid><originalsourceid>FETCH-LOGICAL-c211t-3180863a6d1979f86feff8b864bc65947d297f4644c814f0f0f7947632fbbfd73</originalsourceid><addsrcrecordid>eNpNkMFPwjAUxhujEYPcPJsmXjRx2K6l7bzhRDBgJEbicem21zCUDtvt4Ml_3SpoTA99ef1933v9EDqhpC_lILkqWget7_NEUrKHjmIqVKSo4vv_6g7qeb8ihFAiYyLJIeowRQVVjB2hz3QJxeumrmyDp5XVHnCMz9PJaBpf4DFYwA9to5uqtriyWON5qCGwL1WzxDcOtG-wtiWeu9oHDnCqbQHuGg_xwlbvLYQX8EGx9ahN8HjSDvBt5YMYjtGB0W8eeru7ixZ3o-d0Es0ex_fpcBYVMaVNxKgiSjAtSprIxChhwBiVK8HzQgwSLss4kYYLzgtFuSHhyNAVLDZ5bkrJuuhs67txddjKN9mqbp0NI7M4IYpITikN1OWWKsJ3vAOTbVy11u4joyT7DjzbBp79BB7w051pm6-h_IN_42Vfz3d6ew</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2908074111</pqid></control><display><type>article</type><title>Checkpoint Kinase 2 (CHEK2) Gene Mutation in a Patient With Breast and Prostate Cancer: A Unique Presentation of a Rare Disease</title><source>PMC (PubMed Central)</source><source>Publicly Available Content (ProQuest)</source><creator>Ekram, Samar N ; Al Shanbari, Nasser ; Bin Laswad, Bassam M ; Alharthi, Abdulrahman ; Tayeb, Waseem ; Bahha, Abdulbari</creator><creatorcontrib>Ekram, Samar N ; Al Shanbari, Nasser ; Bin Laswad, Bassam M ; Alharthi, Abdulrahman ; Tayeb, Waseem ; Bahha, Abdulbari</creatorcontrib><description>Breast cancer is one of the rarest malignancies in males, with a low incidence rate compared to all breast cancers. Gene mutation plays a significant role in the pathologic process of cancer. Mutations in breast cancer gene 1 (
) and breast cancer gene 2 (
) have been associated with male breast cancer (MBC), as well as prostate cancer (PCa). Despite the etiopathogenetic similarity, combined MBC and PCa is a rare entity. This report presents the case of a 57-year-old male with a history of breast cancer who underwent modified radical mastectomy (MRM) with lymph node dissection followed by adjuvant chemoradiotherapy four years ago. The patient presented with recurrent episodes of voiding dysfunction for three months, followed by urine retention. His family history was positive for breast and lung cancer. High prostate-specific antigen (PSA) and Prostate Imaging-Reporting and Data System 5 (PI-RADS5) necessitate transrectal ultrasound-guided biopsy, which confirmed the diagnosis of PCa. Molecular genetics testing and next-generation sequencing (NGS) analysis identified heterozygous variant c.636T>G, p.(Tyr212*) in the checkpoint kinase 2 (
) gene. The patient is planned for neoadjuvant luteinizing hormone-releasing hormone (LHRH) for 3-6 months, to be followed by transurethral tunneling of the prostate (TUTP) with adjuvant LHRH. The allele frequency of this patient mutation was documented for the first time among the general population, and it has not been described in the literature. This unique and rare case was presented with clinical, morphological, and immunohistochemical features together with a review of the current literature.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.49710</identifier><identifier>PMID: 38161833</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Breast cancer ; Case reports ; Family medical history ; Magnetic resonance imaging ; Mens health ; Mutation ; Ovarian cancer ; Prostate cancer</subject><ispartof>Curēus (Palo Alto, CA), 2023-11, Vol.15 (11), p.e49710</ispartof><rights>Copyright © 2023, Ekram et al.</rights><rights>Copyright © 2023, Ekram et al. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c211t-3180863a6d1979f86feff8b864bc65947d297f4644c814f0f0f7947632fbbfd73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2908074111/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2908074111?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,25732,27903,27904,36991,44569,74873</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38161833$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ekram, Samar N</creatorcontrib><creatorcontrib>Al Shanbari, Nasser</creatorcontrib><creatorcontrib>Bin Laswad, Bassam M</creatorcontrib><creatorcontrib>Alharthi, Abdulrahman</creatorcontrib><creatorcontrib>Tayeb, Waseem</creatorcontrib><creatorcontrib>Bahha, Abdulbari</creatorcontrib><title>Checkpoint Kinase 2 (CHEK2) Gene Mutation in a Patient With Breast and Prostate Cancer: A Unique Presentation of a Rare Disease</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Breast cancer is one of the rarest malignancies in males, with a low incidence rate compared to all breast cancers. Gene mutation plays a significant role in the pathologic process of cancer. Mutations in breast cancer gene 1 (
) and breast cancer gene 2 (
) have been associated with male breast cancer (MBC), as well as prostate cancer (PCa). Despite the etiopathogenetic similarity, combined MBC and PCa is a rare entity. This report presents the case of a 57-year-old male with a history of breast cancer who underwent modified radical mastectomy (MRM) with lymph node dissection followed by adjuvant chemoradiotherapy four years ago. The patient presented with recurrent episodes of voiding dysfunction for three months, followed by urine retention. His family history was positive for breast and lung cancer. High prostate-specific antigen (PSA) and Prostate Imaging-Reporting and Data System 5 (PI-RADS5) necessitate transrectal ultrasound-guided biopsy, which confirmed the diagnosis of PCa. Molecular genetics testing and next-generation sequencing (NGS) analysis identified heterozygous variant c.636T>G, p.(Tyr212*) in the checkpoint kinase 2 (
) gene. The patient is planned for neoadjuvant luteinizing hormone-releasing hormone (LHRH) for 3-6 months, to be followed by transurethral tunneling of the prostate (TUTP) with adjuvant LHRH. The allele frequency of this patient mutation was documented for the first time among the general population, and it has not been described in the literature. This unique and rare case was presented with clinical, morphological, and immunohistochemical features together with a review of the current literature.</description><subject>Breast cancer</subject><subject>Case reports</subject><subject>Family medical history</subject><subject>Magnetic resonance imaging</subject><subject>Mens health</subject><subject>Mutation</subject><subject>Ovarian cancer</subject><subject>Prostate cancer</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpNkMFPwjAUxhujEYPcPJsmXjRx2K6l7bzhRDBgJEbicem21zCUDtvt4Ml_3SpoTA99ef1933v9EDqhpC_lILkqWget7_NEUrKHjmIqVKSo4vv_6g7qeb8ihFAiYyLJIeowRQVVjB2hz3QJxeumrmyDp5XVHnCMz9PJaBpf4DFYwA9to5uqtriyWON5qCGwL1WzxDcOtG-wtiWeu9oHDnCqbQHuGg_xwlbvLYQX8EGx9ahN8HjSDvBt5YMYjtGB0W8eeru7ixZ3o-d0Es0ex_fpcBYVMaVNxKgiSjAtSprIxChhwBiVK8HzQgwSLss4kYYLzgtFuSHhyNAVLDZ5bkrJuuhs67txddjKN9mqbp0NI7M4IYpITikN1OWWKsJ3vAOTbVy11u4joyT7DjzbBp79BB7w051pm6-h_IN_42Vfz3d6ew</recordid><startdate>20231130</startdate><enddate>20231130</enddate><creator>Ekram, Samar N</creator><creator>Al Shanbari, Nasser</creator><creator>Bin Laswad, Bassam M</creator><creator>Alharthi, Abdulrahman</creator><creator>Tayeb, Waseem</creator><creator>Bahha, Abdulbari</creator><general>Cureus Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20231130</creationdate><title>Checkpoint Kinase 2 (CHEK2) Gene Mutation in a Patient With Breast and Prostate Cancer: A Unique Presentation of a Rare Disease</title><author>Ekram, Samar N ; Al Shanbari, Nasser ; Bin Laswad, Bassam M ; Alharthi, Abdulrahman ; Tayeb, Waseem ; Bahha, Abdulbari</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c211t-3180863a6d1979f86feff8b864bc65947d297f4644c814f0f0f7947632fbbfd73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Breast cancer</topic><topic>Case reports</topic><topic>Family medical history</topic><topic>Magnetic resonance imaging</topic><topic>Mens health</topic><topic>Mutation</topic><topic>Ovarian cancer</topic><topic>Prostate cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ekram, Samar N</creatorcontrib><creatorcontrib>Al Shanbari, Nasser</creatorcontrib><creatorcontrib>Bin Laswad, Bassam M</creatorcontrib><creatorcontrib>Alharthi, Abdulrahman</creatorcontrib><creatorcontrib>Tayeb, Waseem</creatorcontrib><creatorcontrib>Bahha, Abdulbari</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ekram, Samar N</au><au>Al Shanbari, Nasser</au><au>Bin Laswad, Bassam M</au><au>Alharthi, Abdulrahman</au><au>Tayeb, Waseem</au><au>Bahha, Abdulbari</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Checkpoint Kinase 2 (CHEK2) Gene Mutation in a Patient With Breast and Prostate Cancer: A Unique Presentation of a Rare Disease</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2023-11-30</date><risdate>2023</risdate><volume>15</volume><issue>11</issue><spage>e49710</spage><pages>e49710-</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Breast cancer is one of the rarest malignancies in males, with a low incidence rate compared to all breast cancers. Gene mutation plays a significant role in the pathologic process of cancer. Mutations in breast cancer gene 1 (
) and breast cancer gene 2 (
) have been associated with male breast cancer (MBC), as well as prostate cancer (PCa). Despite the etiopathogenetic similarity, combined MBC and PCa is a rare entity. This report presents the case of a 57-year-old male with a history of breast cancer who underwent modified radical mastectomy (MRM) with lymph node dissection followed by adjuvant chemoradiotherapy four years ago. The patient presented with recurrent episodes of voiding dysfunction for three months, followed by urine retention. His family history was positive for breast and lung cancer. High prostate-specific antigen (PSA) and Prostate Imaging-Reporting and Data System 5 (PI-RADS5) necessitate transrectal ultrasound-guided biopsy, which confirmed the diagnosis of PCa. Molecular genetics testing and next-generation sequencing (NGS) analysis identified heterozygous variant c.636T>G, p.(Tyr212*) in the checkpoint kinase 2 (
) gene. The patient is planned for neoadjuvant luteinizing hormone-releasing hormone (LHRH) for 3-6 months, to be followed by transurethral tunneling of the prostate (TUTP) with adjuvant LHRH. The allele frequency of this patient mutation was documented for the first time among the general population, and it has not been described in the literature. This unique and rare case was presented with clinical, morphological, and immunohistochemical features together with a review of the current literature.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>38161833</pmid><doi>10.7759/cureus.49710</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2168-8184 |
ispartof | Curēus (Palo Alto, CA), 2023-11, Vol.15 (11), p.e49710 |
issn | 2168-8184 2168-8184 |
language | eng |
recordid | cdi_proquest_journals_2908074111 |
source | PMC (PubMed Central); Publicly Available Content (ProQuest) |
subjects | Breast cancer Case reports Family medical history Magnetic resonance imaging Mens health Mutation Ovarian cancer Prostate cancer |
title | Checkpoint Kinase 2 (CHEK2) Gene Mutation in a Patient With Breast and Prostate Cancer: A Unique Presentation of a Rare Disease |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T01%3A02%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Checkpoint%20Kinase%202%20(CHEK2)%20Gene%20Mutation%20in%20a%20Patient%20With%20Breast%20and%20Prostate%20Cancer:%20A%20Unique%20Presentation%20of%20a%20Rare%20Disease&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Ekram,%20Samar%20N&rft.date=2023-11-30&rft.volume=15&rft.issue=11&rft.spage=e49710&rft.pages=e49710-&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.49710&rft_dat=%3Cproquest_cross%3E2908074111%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c211t-3180863a6d1979f86feff8b864bc65947d297f4644c814f0f0f7947632fbbfd73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2908074111&rft_id=info:pmid/38161833&rfr_iscdi=true |